Advertisement

Topics

Pancreatic Ductal Adenocarcinoma - Pipeline Review, H1 2015

05:00 EDT 8 Jun 2015 | BioPortfolio Reports

Recently added to the BioPortfolio report store, Pancreatic Ductal Adenocarcinoma - Pipeline Review, H1 2015 is a new report from Global Markets Direct published on 2015-04-28. This 102-page report is available in PDF from $2000.

Pancreatic Ductal Adenocarcinoma - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Pancreatic Ductal Adenocarcinoma - Pipeline Review, H1 2015’, provides an overview of the Pancreatic Ductal Adenocarcinoma’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Pancreatic Ductal Adenocarcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pancreatic Ductal Adenocarcinoma and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Pancreatic Ductal Adenocarcinoma
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Pancreatic Ductal Adenocarcinoma and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Pancreatic Ductal Adenocarcinoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Pancreatic Ductal Adenocarcinoma pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Pancreatic Ductal Adenocarcinoma Overview 8
Therapeutics Development 9
Pipeline Products for Pancreatic Ductal Adenocarcinoma - Overview 9
Pipeline Products for Pancreatic Ductal Adenocarcinoma - Comparative Analysis 10
Pancreatic Ductal Adenocarcinoma - Therapeutics under Development by Companies 11
Pancreatic Ductal Adenocarcinoma - Therapeutics under Investigation by Universities/Institutes 13
Pancreatic Ductal Adenocarcinoma - Pipeline Products Glance 14
Clinical Stage Products 14
Early Stage Products 15
Pancreatic Ductal Adenocarcinoma - Products under Development by Companies 16
Pancreatic Ductal Adenocarcinoma - Products under Investigation by Universities/Institutes 17
Pancreatic Ductal Adenocarcinoma - Companies Involved in Therapeutics Development 18
Centrose Llc 18
Clovis Oncology, Inc. 19
F. Hoffmann-La Roche Ltd. 20
FibroGen, Inc. 21
Gilead Sciences, Inc. 22
Incuron, LLC 23
InvivoGen Therapeutics 24
Medisyn Technologies, Inc. 25
Merck & Co., Inc. 26
Nerviano Medical Sciences S.r.l. 27
OncoMed Pharmaceuticals, Inc. 28
Pfizer Inc. 29
SillaJen Co. Ltd. 30
Pancreatic Ductal Adenocarcinoma - Therapeutics Assessment 31
Assessment by Monotherapy Products 31
Assessment by Target 32
Assessment by Mechanism of Action 34
Assessment by Route of Administration 36
Assessment by Molecule Type 38
Drug Profiles 40
CBL-0137 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
CYL-02 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
demcizumab - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
EDC-1 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
FG-3019 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Hu-5F9G4 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
ipafricept - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
JX-929 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
MK-0752 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
MK-8628 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
momelotinib - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
MRK-003 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
MT-477 - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
NMSP-715 - Drug Profile 63
Product Description 63
Mechanism of Action…

For more information open Pancreatic Ductal Adenocarcinoma - Pipeline Review, H1 2015.

SKU: GMDHC6619IDB

Original Article: Pancreatic Ductal Adenocarcinoma - Pipeline Review, H1 2015

NEXT ARTICLE

More From BioPortfolio on "Pancreatic Ductal Adenocarcinoma - Pipeline Review, H1 2015"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

BioPortfolio - life science, medical devices and pharmaceutical conference
BioPortfolio is a leading news, information and knowledge resource covering the global life science industries impacted on by biotechnology. The site aims to provide the lay person, the researcher and the management executive with a single location to so...

Pancreatitis
Pancreatitis Acute pancreatitis is inflammation of the pancreas caused by the release of activated pancreatic enzymes. Common triggers are biliary tract disease and chronic heavy alcohol intake.  Diagnosis is based on clinical presentation...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...